ReviewMolecular biotechnology1996
Retroviral vectors. From laboratory tools to molecular medicine.
Review in Molecular biotechnology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Transcriptional targeting of tumor endothelial cells for gene therapy.Advanced drug delivery reviews · 2009Review
- Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors.BMC molecular biology · 2009Article
- Influence of particle size and antacid on release and stability of plasmid DNA from uniform PLGA microspheres.Journal of controlled release : official journal of the Controlled Release Society · 2007Article
- Design and development of polymers for gene delivery.Nature reviews. Drug discovery · 2005Review
- Gene transfer in higher animals: theoretical considerations and key concepts.Journal of biotechnology · 2002Review
- Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2activity.Gene therapy · 1999Article
- Two-helper RNA system for production of recombinant Semliki forest virus particles.Journal of virology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of clinical trials for gene therapy currently employ retroviral-mediated gene delivery. This is because the life cycle of the retrovirus is well understood and can be effectively manipulated to generate vectors that can be efficiently and safely packaged. Here, we review the molecular technology behind the generation of recombinant retroviral vectors. We also highlight the problems associated with the use of these viruses as gene therapy vehicles and discuss future developments that will be necessary to maintain retroviral vectors at the forefront of gene transfer technology.
Indexed as
Identifiers
8734426What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.